You are on page 1of 12
MEMORANDUM FOR BOARD MEETING OF 29 JUNE 2005, PHARMAC Directors, Sean Dougherty 21 tune 2005 OXYCODONE HYDROCHLORIDE, Recommendations es recommended that having regard to the decision eriteri set out in Section 2.2 of PHARMAC’S (Operating Policies end Procedres yo resolve fo list oxycodone fyochloride in the Opioid Analgesics therapevic subgroup of ‘Seaton B and in art I'ofSeetionH of the Phamaceutial Schedule fom | August 2008s fellows: Presentation Brand ‘Seengih Pack Sie PrcalSubaiy Capsies Onto Sa Ey 323 Caos one toma = 3588 Cepaes one 2009 = er Cconmolcraease tats OryCantn 10m = sre CConcocreease itis OyComtn 20m = srass Coneolcreess tats OnConin 400 2 sxa20 Contolcreeaselatets___OnCantn 079 ES sea03 revolve to apply the folowing rernction to the presenbing of oxyvodane capsules end ‘conzlledeessed eles in Seton B of the Pharaceutesl Schedule Only ona controled de frm, resolve to apply the following guideline to the presribing of oxycodone capsules and contllod ceased tablets in Secon Bf he Pharmaceutical Sshedue: Prescribing Gatdeline Presrbers should note hat oxycodone is significantly more expensive thn ong acting ‘morphine sulphate and clinical vie suggests tai s reasonable to consider tis asa Seeondiine agent oe used afer morphine note tat the agreement provides for the isting ofthe flowing presentation stuld regulatory pprovl and other consents be granted: ‘Seongth Peck Sze PrcelBubeay ‘Oxycone 5 a S751 resolve to approve the 17 May 2005 agreement with Mundipharma New Zealand Limited in ts entity 5.1.20 91139 1 Supplier [MOH Restretons ‘OxyNom, OxyConin—_—_Chemleal Name Presentation Opioid amigesis Nervous Pharmaceutical Type Sen) Manila New Zea Applcaton Date Time Cones Drag (53) ‘Oneedane yocterise ‘soled eleaee ew cere entity ‘Aes 2004 ‘Careat eb NI Proposed subsidy Caples 5285 per20 sss8per20 $9.7 per20 Controle abet $781 per20 siti per20 1893 per20 33329 pec20 $5803 per 20 Proposed restriction Olona contol dg fom. or Na Secon F % Market ata VERO Tawa E30 Te 2007 YEW Tne 2008 Subsidy Grom) se4o00 1,200,000 1,800,000 Net eos to Schedule san 00 93000 200,000 Net cost to Dt 2000 830,000 200,000 Net os to DUBS (NPV) $s,000,000 10 Ss (rom) ~ forecast of spnting on oxycodone tthe propose subs 2. Natecu to Sele = foes of thang tol spending on pharmacticalsted onthe Sched empath ts goo ‘Nitou o Dis = Net cost te Seed Alco are expese ex mauler, eacoing OS [NPV isclaltod ove $year using am noma dssun rate of 10% Catto in Doe 057725 5.4.20 #91139 Executive Summary ‘Key Issues inthe Proposal + Listing oxycodone, a strong opioid analgesic, inthe Pharmaceutical Schedule would provide an tlernative teatment option to morphine sulphate tablets and eapsues. It has simi efficcy and tolerability, but will allow for opoid rotation and further weatment options whea marine Is aot tolemte, + fy 2002, the review of analgesic agent by tbe newly formed Analgesic and Antiemetic SuBcommtee of PTAC (now the Analgesic Somme of PTAC) highlights several gaps in ‘he publicly iunded lst of analgesic agents; the Subcammitee recommended that PHARMAC Ist, nother song opioid analgesic as an alternative to morphine. ‘+ ‘The Analgesic Review Board paper in April 2005 highlighted fare tke gaps in analgesia treatment available in New Zealand, and noted that PHARMAC staff were pursuing the listing of ‘erycodane a a aerate stongopiid analgesic ‘+The listing of oxycodone in Sein B of the Pharmaceutical Schedule would be ssoiated with 3 small cost increase inthe fist ew year, withthe estited increase in expend in the fh ‘ar being les han $2,000,009. ‘Why Proposl not desided under Delegated Authority ‘The proposal outlined inthis Board paper tus not been dealt with by the CEO ander detested suthry beste the Board has requested o be fvolved in ll erent investment deshions ‘The proposal + Listing oxyeodane hytochlorde capsules and controlled lease tbls in Section 8 ain Pat TL ‘of Secon Hof he Pharmaceutical Sehodule + Listing further presentation ofthe contol release tablet later ime following registro, [Note an agreement, consional on consulation and Board approval, between Midian New Zealand Limited and PHARMAC dated 17 May 2005 is atached ss Appendix 1 timate oft fects of the proposal Given the experience of oxycodone in Ansell, PHARMAC staff ancpate thatthe market for ‘oxyeodone wil prow gradually, increasing make sare ove long-acting morphine by around 5% per yea. Overall marketshare i anticipated abe: nam Ee a 0 es AO 6 15% 20% 25%, 30% Shortactng asycodone The Hinting of the shortacting formulation i anticipated to have 4 minimal efeet on the pharmaceutical budget. Is pricing is substantially lower per tblet than th equivalent dose of shor- ‘Soting formulations of morphine sulphate, vie 5.4.20 491139 3

You might also like